Growth offset by profitability squeeze; Dombivli early ramp awaits insurance empanelment

25–30% occupancy Q1, ₹9.5 Cr EBITDA drag Q1 (matches ₹2–3 Cr/month estimate)

Thane at 75% occ (mature), Pune 60–65% occ (maturing), Indore 50% with team buildup cost ~₹2 Cr

Revenue +18.2% YoY but PAT −14.5% YoY; margin compressed by Dombivli drag and Indore expansion costs

Delivered ₹73,500 ARPOB; drivers cited as mix improvement + insurance renegotiations (confirmed)

Maintained 1.5–2 years despite Q1 occupancy of 25–30% (which suggests possible acceleration). MD conservative: 'Let's see how next 1–2 quarters perform.' Shows discipline, not confidence upgrade.

Thane now 75% occ (only inflation growth ahead), Pune 60–65% approaching saturation (15% occ growth remaining). Relative to prior 'strong growth across 3 hospitals,' momentum clearly slowing.

Acquired IV fluids manufacturing (₹35–40 Cr) for cost/margin improvement at 3,000-bed scale. Positioned as pharmacy subsidiary, not pharma entry. Small but signals margin-enhancement thinking.

Analyst asked for 20–21% full-year OPM; MD declined to give explicit number, said 'model it yourself' using Dombivli drag + mature hospital inputs. Prior calls had more concrete guidance tone.

Team buildups and doctor hires for next-phase expansion (~₹2 Cr new hires); higher HR costs anticipated. Occupancy improvement underway rest of year.

Fixed cost ₹6–7 Cr/month currently. Doctor hiring ongoing for 2+ years (adding subspecialties progressively).

Phase 1 (1–2 yr initial loss), Phase 2: when occupancy hits 60%, add capacity to drop it back to ~40% (margin compression but no loss). Cycle repeats. Losses only in initial 1–2 yr.

Two drivers: case mix improvement + insurance contract renegotiations (ongoing). Mature units: inflation-linked; new units: higher than inflation initially (case mix), then inflation at maturity.

Must model: 3 mature hospitals' contribution + Dombivli ₹2–3 Cr/month loss guidance. No explicit target given; analyst to project.

Yes, guidance still holds. Conservative approach; want to see next 1–2 quarters.

Backward integration for margin/cost improvement at 3,000-bed scale. ₹35–40 Cr capex—immaterial vs. hospital capex. Not entry into pharma; hospital company with integrated pharmacy.

Thane and Pune similar profiles now. Q1/Q3 seasonally weak, Q2/Q4 strong. Dombivli drag this quarter. Likely no gap between Thane/Pune margins.

Correct. Pune can go 60% → 75% (15% growth opportunity left). Growth will plateau vs. earlier sharp ramp. Base now higher, so % growth lower.

Based on insurance assumptions and past experience. Don't want to be aggressive with 1 quarter data. Will revisit if next 1–2 qtr data supports.

Capex spec in presentation. Internal accruals + cash should cover next few years. May need debt towards end of cycle. Ceiling 3x EBITDA, expect to stay within.

Non-promoter pledge by somebody else. Stock split caused 5x share increase; pledge amount unchanged (filing corrected). Net debt ~0 (₹500 Cr debt, ₹500 Cr cash).

Only 5-year visibility now: deliver 3 announced projects in 5 years. Strong demand-supply gap in organized healthcare, especially West India. Will continue building more hospitals of same style. Focus West India.

Currently all self-paid with some reimbursement + pre-authorized insurance. Large mix only after empanelment done. Can't quantify occ bump, but empanelment will reduce friction, should improve footfall.

Yes, ₹500 Cr includes capex debt increase. Exact number in uploaded financials. Confirm finance cost higher due to debt uptick.

Not immediately; could consider with revised pricing in future. Not right away.

Oncology yet to launch. Radiation and LINAC should come by end of year.

Premium location chosen intentionally. Not resident-heavy but highly accessible; 45-min drive covers 50%+ of Mumbai. 100m from bullet train. Most accessible location in Bombay.

Gradual month-on-month increase. Ramping well (both doctor interest and patient demand). Expects consistent ramp until breakeven (year 2). Insurance empanelment will further improve footfall.

Dombivli added Q1 FY27, expected to ramp. 3 mature hospitals (Thane, Pune, Indore) also growing. No specific FY27 target, but 18.2% YoY pace maintained.

Q1 result ₹9.5 Cr drag consistent with ₹2.5 Cr avg/month. Guidance held despite Q1 strong occupancy ramp.

MD told analysts to model using: 3 mature hospital profiles + Dombivli drag + Indore growth investments. Evasion suggests confidence gap or complexity.

Toward end of capex cycle may require debt; debt ceiling 3x EBITDA (board-imposed). Specific capex numbers withheld from transcript (refer to PPT).

Dombivli breakeven in 1.5–2 yr depends on insurance empanelment (not yet complete) and occupancy acceleration from 25–30% to 50–60%. If empanelment delayed or occupancy stalls, breakeven slips, PAT remains under pressure.

Thane at 75% occ (only inflation growth ahead), Pune at 60–65% occ (~15% occ growth left). As largest revenue contributors mature, consolidated growth dependent on new projects (Dombivli, Pune South, Mira Road, BKC). If ramp-ups disappoint, group CAGR falls.

Revenue +18.2% YoY but PAT −14.5% YoY. Dombivli drag and Indore expansion investments explain most; but indicates operating leverage not yet realized. If new hospitals don't ramp faster, PAT pressure persists.

3 new hospitals lined up (Pune South, Mira Road, BKC); Dombivli Phase 2 expansion to 300 beds planned. Capex outlined in PPT (not in transcript). MD said internal accruals + cash will cover next few years, but debt may be needed towards end. Debt now ₹500 Cr (up from ₹509 Cr prior year, nearly flat); if capex accelerates or occupancy ramp slows, debt upside risk.

Dombivli still entirely self-paid or reimbursement-based insurance (no large empanelled insurance mix yet). If insurance company empanelment terms unfavorable or delayed, or if pricing power weakens across payer mix, ARPOB growth could stall.